Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Analysts

Key Points

• Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus rating of "Buy" from ten analyst firms, with an average target price of approximately $32.25.
• Shares of Bicara Therapeutics are currently trading at $11.71, with a 12-month low of $7.80 and a high of $28.09.
• The company is in the clinical-stage of developing bifunctional therapies for solid tumors, with its lead program focusing on a novel treatment, ficerafusp alfa.

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given a consensus rating of "Buy" by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $32.2513.

BCAX has been the topic of a number of analyst reports. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. Piper Sandler started coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 target price on the stock. Finally, HC Wainwright reduced their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, August 22nd.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $25,000. CWM LLC purchased a new stake in Bicara Therapeutics in the first quarter valued at $29,000. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after acquiring an additional 1,233 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Bicara Therapeutics in the fourth quarter valued at $32,000. Finally, Ameritas Investment Partners Inc. lifted its position in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter.

Bicara Therapeutics Trading Up 9.4%

Shares of BCAX opened at $11.71 on Friday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $28.09. The stock has a fifty day moving average price of $11.39 and a 200-day moving average price of $11.59. The firm has a market cap of $638.90 million and a PE ratio of -3.69.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. As a group, research analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.